Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

A Pre-Surgical, Randomized Clinical Trial of Genistein in Resectable Pancreatic Adenocarcinoma

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00882765

Enrollment

Registered

2009-04-16

Start date

2009-05-31

Completion date

Unknown

Last updated

2020-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

adenocarcinoma of the pancreas, stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer

Brief summary

RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving genistein before surgery may be an effective treatment for pancreatic cancer. PURPOSE: This randomized phase II trial is studying genistein to see how well it works in treating patients with pancreatic cancer that can be removed by surgery.

Detailed description

OBJECTIVES: Primary * To determine changes in microvessel density of the tumor specimen after 2 weeks of treatment with genistein in patients with resectable pancreatic adenocarcinoma. Secondary * To evaluate the safety and tolerability of genistein in these patients by looking at the impact of genistein on pancreatic cancer angiogenesis and on the angiogenic factors VEGF, CXCL1, CXCL5, and CXCL8. OUTLINE: Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive neoadjuvant oral genistein once daily for 2 weeks in the absence of disease progression or unacceptable toxicity. * Arm II: Patients receive no specific neoadjuvant therapy. In both arms, patients undergo surgical resection in week 3. Blood, urine, and tissue samples are collected at baseline and at the time of surgery for laboratory biomarker studies. Samples are analyzed for VEGF, CXCL1, CXCL5, and CXCL8 by ELISA and for genistein by mass spectrometry.

Interventions

DIETARY_SUPPLEMENTgenistein

Given orally

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults over the age of 18 capable of giving informed consent * resectable pancreatic mass, known or presumed to be primary pancreatic adenocarcinoma. Patients whose initial biopsy do not show adenocarcinoma will not receive the study drug. * ECOG preformance status 0-2. * Negative pregnancy test prior to initiation of treatment and adequate contraception throughout treatment.

Exclusion criteria

* comorbid disease or medical condition that would impair the ability of the patient to receive or comply with the study protocol * hypersensitivity to genistein or to any of the excipients of genistein * prior chemotherapy or radiotherapy for pancreatic adenocarcinoma * concomitant use of warfarin, tamoxifen, or raloxifene. * pregnancy or inadequate contraception. * lactating females

Design outcomes

Primary

Measure	Time frame
Changes in microvessel density of tumor specimen after 2 weeks of treatment with genistein	2 weeks

Secondary

Measure	Time frame
To evaluate the impact of genistein on the angiogenic factors VEGF, CXCL1, CXCL5, and CXCL8	3 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026